I was told it was a temporary skin rash often caused by viral infections ... the biopsy came back identifying plaque psoriasis, a chronic autoimmune skin condition that manifests as scaly patches ...

Medically reviewed by Casey Gallagher, MD Armpit rashes often develop due to allergic reactions, infections, and chronic ...

Psoriasis can look like a rash, so you may worry that you could ... It comes in several forms. Plaque psoriasis is the most common. Plaque psoriasis, the most common form of psoriasis, is a ...

Late-breaking data supported the efficacy of icotrokinra, an interleukin-23 inhibitor, for plaque psoriasis. By week 24, 46% of icotrokinra-treated patients achieved IGA 0 and 40% reached PASI 100.

Traditional psoriasis is called plaque psoriasis or psoriasis vulgaris. It usually causes flaky patches of skin in small parts of the body, like the elbows or scalp. Researchers initially thought ...

Zoryve (roflumilast) is a prescription drug that’s used to treat plaque psoriasis, atopic dermatitis, and seborrheic dermatitis in adults and certain children. Zoryve comes as a topical cream or ...

Once-daily ICP-488 significantly improved PASI scores in patients with plaque psoriasis compared with placebo at week 12. The safety profile of ICP-488 was similar to placebo. ORLANDO — A once ...

Even though he suffers from psoriasis, Joel Thomas considers himself a lucky man. Psoriasis is a chronic skin disorder that affects over seven and a half million Americans. Many are not as lucky ...

Sustained complete skin clearance over five years: In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% of patients with moderate-to-severe plaque psoriasis (PSO) treated with ...

(ALMS) announced positive 52-week data from the open-label extension (OLE) of its Phase 2 STRIDE clinical trial evaluating ESK-001 in patients with moderate-to-severe plaque psoriasis. According ...

(RTTNews) - Johnson & Johnson (JNJ) announced new icotrokinra (JNJ-2113) data from its Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis (PsO ...